Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) will report first quarter 2026 financial results on May 4, 2026 before U.S. markets open and host a conference call at 8:00 a.m. ET.

Investors can join via domestic dial-in (877) 405-1239, international +1 (201) 389-0851, or a live webcast on the company’s Investors > Webcasts & Presentations page. A replay will be available on the website for about 30 days after the event.

News Market Reaction – AXSM

+2.64%

+2.64% Session close to close

In the Apr 8 session, AXSM gained 2.64%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Axsome’s Q1 2026 financial results and conference call at 8:00...

Analysis

This announcement sets the timing for Axsome’s Q1 2026 financial results and conference call at 8:00 a.m. ET on May 4, 2026, continuing its pattern of scheduled disclosures. In context of prior strong 2025 revenue growth and a pending April 30, 2026 PDUFA date for AXS-05, investors may focus on how new numbers compare with past performance and on ongoing pipeline and acquisition updates as they are reported.

Key Figures

4Q 2025 net product revenue: $196.0M FY 2025 net product revenue: $638.5M 4Q 2025 revenue growth: 65% +5 more

8 metrics

4Q 2025 net product revenue $196.0M Fourth quarter 2025 results

FY 2025 net product revenue $638.5M Full year 2025 results

4Q 2025 revenue growth 65% Year-over-year growth in 4Q 2025

FY 2025 revenue growth 66% Year-over-year growth for full year 2025

Cash balance $322.9M As reported in 4Q and FY 2025 update

PDUFA date April 30, 2026 AXS-05 in Alzheimer’s disease agitation

Phase 2 sample size 164 patients Balipodect proof-of-concept trial in schizophrenia

Clinical subjects Over 360 individuals Balipodect safety and tolerability studies

Previous Earnings date Reports

1 past event · Latest: Jan 27 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 27	Earnings date announcement	Neutral	+1.9%	Set timing for 4Q and full-year 2025 results with investor call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For similar earnings-date announcements, AXSM previously saw a mild positive move, suggesting modest anticipatory interest rather than large dislocations.

Recent Company History

Recent AXSM news highlighted strategic expansion and strong fundamentals. On Feb 23, 2026, the company reported $196.0M in 4Q 2025 and $638.5M full-year revenue with solid growth and a cash balance of $322.9M. Subsequent updates included a Phase 3 trial initiation and the balipodect acquisition. Today’s first-quarter earnings date notice continues the pattern of scheduled financial disclosures with accompanying business updates and conference calls.

Key Terms

pdufa, phase 3, phase 2, restricted stock units, +4 more

8 terms

pdufa regulatory

"a PDUFA date of April 30, 2026 for AXS-05 in Alzheimer’s disease agitation."

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

phase 3 medical

"Axsome plans Phase 3 trial-enabling activities in 2026."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2 medical

"Balipodect completed a 164-patient Phase 2 proof-of-concept in schizophrenia"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

restricted stock units financial

"received a grant of 54,623 restricted stock units. Each RSU represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"received a grant of 18,570 Restricted Stock Units (RSUs) on February 26, 2026."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

rule 10b5-1 trading plan regulatory

"as part of a pre‑approved Rule 10b5‑1 trading plan that has now been completed."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

schedule 13g regulatory

"filed an amendment to a Schedule 13G reporting its beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

cashless exercise financial

"the planned method is a cashless exercise / same-day sale through Goldman Sachs"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2026 on Monday, May 4, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A replay of the conference call will be available on the Company’s website for approximately 30 days following the live event.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI^®, AUVELITY^®, and SYMBRAVO^® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

FAQ

When will Axsome Therapeutics (AXSM) report Q1 2026 results and what time is the call?

Axsome will report Q1 2026 results on May 4, 2026, before U.S. markets, with a conference call at 8:00 a.m. ET. According to the company, management will discuss the results and provide a business update during the call.

How can investors listen to Axsome (AXSM) Q1 2026 earnings call on May 4?

Investors can dial (877) 405-1239 (U.S.) or +1 (201) 389-0851 (international) to join the call. According to the company, a live webcast will also be available on the Investors > Webcasts & Presentations page of the company website.

Will Axsome (AXSM) provide a replay of the May 4, 2026 conference call?

Yes. A replay of the conference call will be available on the company website for about 30 days after the live event. According to the company, the replay will be posted on the Investors > Webcasts & Presentations page.

What will Axsome management cover on the May 4, 2026 conference call for AXSM?

Management will discuss first quarter 2026 financial results and provide a business update during the call. According to the company, the session is intended to review performance and offer context for investors and analysts.

Where can I find the Axsome (AXSM) webcast and related presentation materials for May 4, 2026?

The live webcast and any presentation materials will be available on the company website under Investors > Webcasts & Presentations. According to the company, materials and the webcast link will be posted before the call begins.

Are international listeners able to access Axsome's (AXSM) May 4, 2026 earnings call?

Yes. International participants can join by dialing +1 (201) 389-0851 or by using the live webcast on the company site. According to the company, both dial-in and webcast options are provided for global access.